Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 29 05 2019
accepted: 24 10 2019
pubmed: 7 11 2019
medline: 28 11 2019
entrez: 7 11 2019
Statut: ppublish

Résumé

L-arginine depletion by regulatory cells and cancer cells expressing arginase-1 (Arg-1) is a vital contributor to the immunosuppressive tumor microenvironment in patients with cancer. We have recently described the existence of pro-inflammatory effector T cells that recognize Arg-1. Hence, Arg-1-specific self-reactive T cells are a naturally occurring part of the memory T-cell repertoire of the human immune system. Here, we further characterize a highly immunogenic epitope from Arg-1. We describe frequent T-cell-based immune responses against this epitope in patients with cancer, as well as in healthy donors. Furthermore, we show that Arg-1-specific T cells expand in response to the T

Identifiants

pubmed: 31690955
doi: 10.1007/s00262-019-02425-6
pii: 10.1007/s00262-019-02425-6
doi:

Substances chimiques

Cancer Vaccines 0
Epitopes, T-Lymphocyte 0
Arginase EC 3.5.3.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1901-1907

Auteurs

Evelina Martinenaite (E)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
IO Biotech ApS, 2200, Copenhagen, Denmark.

Shamaila Munir Ahmad (SM)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.

Simone Kloch Bendtsen (SK)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.

Mia Aaboe Jørgensen (MA)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.

Stine Emilie Weis-Banke (SE)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.

Inge Marie Svane (IM)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.

Mads Hald Andersen (MH)

National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark. mads.hald.andersen@regionh.dk.
IO Biotech ApS, 2200, Copenhagen, Denmark. mads.hald.andersen@regionh.dk.
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. mads.hald.andersen@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH